The first patient expert training course of the European Patients' Academy (EUPATI) has begun.
The first patient expert training course of the European Patients’ Academy (EUPATI) has begun. The 15-month program is designed to meet the needs of patients and patient representatives and to impart expert knowledge about the whole spectrum of the medicine research and development process.
“The course is specifically designed to meet the needs of participants who are motivated with the skill set to acquire and apply this expert-level knowledge,” said Jan Geissler, EUPATI Director, who noted that earlier this month a webinar marked the official opening of the course and the launch of the online learning program for 53 participants.
The course comprises a mixture of online and face-to-face training and covers discovery, development, evaluation, marketing authorization and post-marketing evaluation, and other important subjects. Participants will take six e-learning modules covering a broad range of topics. They will also attend two face-to-face training events for interactive teaching and have the opportunity to meet directly with other patient experts and with specialists working in the field of medicine development.
The organizers plan to encourage participants to apply knowledge and skills acquired through three main areas:
The second wave of the program will start in September 2015. By 2016, there will be over 100 expert patients who will be able to share their expertise and help to reach the patient community, raise public awareness and generate dialogue around future patient involvement in research and development.
EUPATI received more than 300 applications for the course. An independent evaluation panel selected 53 participants based upon careful examination of all eligible applications against the pre-defined selection criteria. The application period for next year's EUPATI course will start in spring 2015.
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.